MACM
AERI

March Altus Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

March Altus Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-14,962
Closed -$364K – 11
2015
Q4 		$364K Sell
14,962
-16,000
-52% -$373K 3.35% 9
2015
Q3 		$549K Buy
+30,962
New +$561K 3.23% 13

Other funds holding AERI

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

March Altus Capital Management's AERI Position: Q1 2016 in Review

March Altus Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2016, closing a stake of 14,962 shares — an estimated $364K sold.

March Altus Capital Management first reported a position in AERI in Q3 2015 and held it in 2 quarters. The position peaked at $549K in Q3 2015. 102 funds tracked by Wall St. Rank hold AERI as of Q1 2016.

  • March Altus Capital Management reported no remaining Aerie Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • March Altus Capital Management sold 14,962 Aerie Pharmaceuticals shares in Q1 2016, an estimated $364K.
  • March Altus Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • March Altus Capital Management's Aerie Pharmaceuticals position peaked at $549K in Q3 2015.
  • 102 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2016.

Based on March Altus Capital Management's 13F filing for Q1 2016, filed 12 May 2016.